QR код

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD

The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial clinical effects, these medications have an impact...

Повний опис

Збережено в:
Автори: E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov
Формат: Artigo
Мова:Russo
Опубліковано: IRBIS LLC 2017-08-01
Серія:Фармакоэкономика
Предмети:
chronic obstructive pulmonary disease
copd
long-acting beta-agonists
laba
long-acting anticholinergics
laac
vilantererol
umeclidinum bromide
olodaterol
tiotropium bromide
fixed combination
cost minimization analysis
cost-effectiveness analysis
budget impact analysis
Онлайн доступ:https://www.pharmacoeconomics.ru/jour/article/view/196
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси